$PGNX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PROGENICS PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PROGENICS PHARMACEUTICALS INC. Get notifications about new insider transactions in PROGENICS PHARMACEUTICALS INC for free.
Page: < prev 1 ... 4 5 6 7 8 9 10 11 12 ... 13 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | M | 20.13 | 621 | 12,501 | 0 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Payment of Exercise | F | 24.10 | 560 | 13,496 | 11,065 | 11.6 K to 11.1 K (-4.82 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Buy | M | 20.13 | 621 | 12,501 | 11,625 | 11 K to 11.6 K (+5.64 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 147,000 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | A | 20.13 | 1,809 | 36,415 | 1,809 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 20.13 | 1,754 | 35,308 | 0 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Payment of Exercise | F | 24.10 | 1,581 | 38,102 | 657,290 | 658.9 K to 657.3 K (-0.24 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 20.13 | 1,754 | 35,308 | 658,871 | 657.1 K to 658.9 K (+0.27 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 23.85 | 12,000 | 286,152 | 657,117 | 669.1 K to 657.1 K (-1.79 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 669,117 | 657.1 K to 669.1 K (+1.83 %) |
| Apr 03 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | A | 12.58 | 1,250 | 15,728 | 1,250 | |
| Mar 19 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 17.19 | 1,500 | 25,785 | 7,500 | |
| Mar 19 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 13.63 | 500 | 6,813 | 2,500 | |
| Mar 19 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 22.77 | 500 | 11,385 | 33,676 | 34.2 K to 33.7 K (-1.46 %) |
| Mar 19 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 13.63 | 500 | 6,813 | 34,176 | 33.7 K to 34.2 K (+1.48 %) |
| Mar 19 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 22.80 | 1,500 | 34,197 | 33,676 | 35.2 K to 33.7 K (-4.26 %) |
| Mar 19 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 17.19 | 1,500 | 25,785 | 35,176 | 33.7 K to 35.2 K (+4.45 %) |
| Mar 19 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 159,000 | |
| Mar 19 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 22.95 | 12,000 | 275,424 | 657,117 | 669.1 K to 657.1 K (-1.79 %) |
| Mar 19 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 669,117 | 657.1 K to 669.1 K (+1.83 %) |
| Mar 02 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 171,000 | |
| Mar 02 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 26.49 | 12,000 | 317,832 | 657,117 | 669.1 K to 657.1 K (-1.79 %) |
| Mar 02 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 669,117 | 657.1 K to 669.1 K (+1.83 %) |
| Feb 22 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Grant | A | 0.00 | 15,957 | 0 | 657,117 | 641.2 K to 657.1 K (+2.49 %) |
| Mar 02 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | M | 4.00 | 10,000 | 40,000 | 0 | |
| Mar 02 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Sell | S | 25.99 | 10,000 | 259,890 | 32,181 | 42.2 K to 32.2 K (-23.71 %) |
| Mar 02 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Buy | M | 4.00 | 10,000 | 40,000 | 42,181 | 32.2 K to 42.2 K (+31.07 %) |
| Feb 20 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 183,000 | |
| Feb 20 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 29.89 | 12,000 | 358,716 | 641,160 | 653.2 K to 641.2 K (-1.84 %) |
| Feb 20 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 653,160 | 641.2 K to 653.2 K (+1.87 %) |
| Feb 20 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 17.19 | 4,000 | 68,760 | 8,000 | |
| Feb 20 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 29.97 | 4,000 | 119,896 | 33,676 | 37.7 K to 33.7 K (-10.62 %) |
| Feb 20 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 17.19 | 4,000 | 68,760 | 37,676 | 33.7 K to 37.7 K (+11.88 %) |
| Feb 14 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 4.00 | 4,000 | 16,000 | 0 | |
| Feb 14 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Sell | S | 29.48 | 4,000 | 117,908 | 22,694 | 26.7 K to 22.7 K (-14.98 %) |
| Feb 14 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 4.00 | 4,000 | 16,000 | 26,694 | 22.7 K to 26.7 K (+17.63 %) |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | M | 4.00 | 5,000 | 20,000 | 10,000 | |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | M | 4.00 | 5,000 | 20,000 | 15,000 | |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | M | 4.00 | 10,000 | 40,000 | 20,000 | |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | M | 4.00 | 10,000 | 40,000 | 30,000 | |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Sell | S | 30.05 | 5,000 | 150,250 | 32,181 | 37.2 K to 32.2 K (-13.45 %) |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Buy | M | 4.00 | 5,000 | 20,000 | 37,181 | 32.2 K to 37.2 K (+15.54 %) |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Sell | S | 30.08 | 5,000 | 150,400 | 32,181 | 37.2 K to 32.2 K (-13.45 %) |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Buy | M | 4.00 | 5,000 | 20,000 | 37,181 | 32.2 K to 37.2 K (+15.54 %) |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Sell | S | 30.10 | 10,000 | 301,000 | 32,181 | 42.2 K to 32.2 K (-23.71 %) |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Buy | M | 4.00 | 10,000 | 40,000 | 42,181 | 32.2 K to 42.2 K (+31.07 %) |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Sell | S | 30.15 | 10,000 | 301,500 | 32,181 | 42.2 K to 32.2 K (-23.71 %) |
| Feb 06 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Buy | M | 4.00 | 10,000 | 40,000 | 42,181 | 32.2 K to 42.2 K (+31.07 %) |
| Jan 31 2007 | PGNX | PROGENICS PHARMACE ... | BAKER CHARLES A | Director | Option Exercise | M | 19.50 | 2,500 | 48,750 | 0 | |
| Jan 31 2007 | PGNX | PROGENICS PHARMACE ... | BAKER CHARLES A | Director | Sell | S | 30.02 | 2,500 | 75,050 | 21,481 | 24 K to 21.5 K (-10.42 %) |
| Jan 31 2007 | PGNX | PROGENICS PHARMACE ... | BAKER CHARLES A | Director | Buy | M | 19.50 | 2,500 | 48,750 | 23,981 | 21.5 K to 24 K (+11.64 %) |
| Feb 02 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 195,000 | |
| Feb 02 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 29.89 | 12,000 | 358,632 | 641,160 | 653.2 K to 641.2 K (-1.84 %) |
| Feb 02 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 653,160 | 641.2 K to 653.2 K (+1.87 %) |
| Jan 31 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 4.00 | 4,000 | 16,000 | 4,000 | |
| Jan 31 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Sell | S | 29.72 | 4,000 | 118,872 | 22,694 | 26.7 K to 22.7 K (-14.98 %) |
| Jan 31 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 4.00 | 4,000 | 16,000 | 26,694 | 22.7 K to 26.7 K (+17.63 %) |
| Jan 18 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 4.00 | 4,000 | 16,000 | 8,000 | |
| Jan 18 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Sell | S | 28.79 | 4,000 | 115,160 | 22,694 | 26.7 K to 22.7 K (-14.98 %) |
| Jan 18 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 4.00 | 4,000 | 16,000 | 26,694 | 22.7 K to 26.7 K (+17.63 %) |
| Jan 18 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 207,000 | |
| Jan 18 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 28.58 | 12,000 | 342,912 | 641,160 | 653.2 K to 641.2 K (-1.84 %) |
| Jan 18 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 653,160 | 641.2 K to 653.2 K (+1.87 %) |
| Jan 10 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | M | 4.00 | 8,000 | 32,000 | 40,000 | |
| Jan 10 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Buy | M | 4.00 | 8,000 | 32,000 | 32,181 | 24.2 K to 32.2 K (+33.08 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | A | 13.62 | 1,250 | 17,030 | 1,250 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | M | 21.88 | 362 | 7,921 | 0 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | A | 25.74 | 335 | 8,623 | 335 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Payment of Exercise | F | 26.66 | 323 | 8,611 | 24,051 | 24.4 K to 24.1 K (-1.33 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Buy | M | 21.88 | 362 | 7,921 | 24,374 | 24 K to 24.4 K (+1.51 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 4.00 | 4,000 | 16,000 | 12,000 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | A | 25.74 | 395 | 10,167 | 395 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 21.88 | 428 | 9,365 | 0 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Payment of Exercise | F | 26.66 | 382 | 10,184 | 22,694 | 23.1 K to 22.7 K (-1.66 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 21.88 | 428 | 9,365 | 23,076 | 22.6 K to 23.1 K (+1.89 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Sell | S | 25.68 | 4,000 | 102,708 | 22,597 | 26.6 K to 22.6 K (-15.04 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 4.00 | 4,000 | 16,000 | 26,597 | 22.6 K to 26.6 K (+17.70 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Option Exercise | M | 21.88 | 686 | 15,010 | 0 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Option Exercise | A | 25.74 | 624 | 16,062 | 624 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Payment of Exercise | F | 26.66 | 612 | 16,316 | 23,187 | 23.8 K to 23.2 K (-2.57 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Buy | M | 21.88 | 686 | 15,010 | 23,799 | 23.1 K to 23.8 K (+2.97 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 219,000 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | A | 25.74 | 1,441 | 37,091 | 1,441 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 21.88 | 1,614 | 35,314 | 0 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Payment of Exercise | F | 26.66 | 1,441 | 38,417 | 641,160 | 642.6 K to 641.2 K (-0.22 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 21.88 | 1,614 | 35,314 | 642,601 | 641 K to 642.6 K (+0.25 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 25.68 | 12,000 | 308,124 | 640,987 | 653 K to 641 K (-1.84 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 652,987 | 641 K to 653 K (+1.87 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | A | 25.74 | 586 | 15,084 | 586 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 21.88 | 643 | 14,069 | 0 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Payment of Exercise | F | 26.66 | 574 | 15,303 | 26,810 | 27.4 K to 26.8 K (-2.10 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 21.88 | 643 | 14,069 | 27,384 | 26.7 K to 27.4 K (+2.40 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | A | 25.74 | 395 | 10,167 | 395 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 21.88 | 428 | 9,365 | 0 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Payment of Exercise | F | 26.66 | 382 | 10,184 | 33,625 | 34 K to 33.6 K (-1.12 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 21.88 | 428 | 9,365 | 34,007 | 33.6 K to 34 K (+1.27 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | A | 25.74 | 522 | 13,436 | 522 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | M | 21.88 | 571 | 12,493 | 0 | |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Payment of Exercise | F | 26.66 | 510 | 13,597 | 10,953 | 11.5 K to 11 K (-4.45 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Buy | M | 21.88 | 571 | 12,493 | 11,463 | 10.9 K to 11.5 K (+5.24 %) |
| Jan 05 2007 | PGNX | PROGENICS PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | A | 26.66 | 25,000 | 666,500 | 25,000 | |
| Nov 14 2006 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 4.00 | 5,000 | 20,000 | 10,000 | |
| Nov 14 2006 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Sell | S | 28.00 | 5,000 | 140,000 | 26,690 | 31.7 K to 26.7 K (-15.78 %) |
| Nov 14 2006 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 4.00 | 5,000 | 20,000 | 31,690 | 26.7 K to 31.7 K (+18.73 %) |
| Dec 19 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 17.19 | 500 | 8,595 | 11,500 | |
| Dec 19 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 17.19 | 1,500 | 25,785 | 12,000 | |
| Dec 19 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 26.05 | 500 | 13,025 | 33,579 | 34.1 K to 33.6 K (-1.47 %) |
| Dec 19 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 17.19 | 500 | 8,595 | 34,079 | 33.6 K to 34.1 K (+1.49 %) |
| Dec 19 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 26.05 | 1,500 | 39,075 | 33,579 | 35.1 K to 33.6 K (-4.28 %) |
| Dec 19 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 17.19 | 1,500 | 25,785 | 35,079 | 33.6 K to 35.1 K (+4.47 %) |
| Dec 19 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 231,000 | |
| Dec 19 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 26.14 | 12,000 | 313,668 | 640,987 | 653 K to 641 K (-1.84 %) |
| Dec 19 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 652,987 | 641 K to 653 K (+1.87 %) |
| Dec 12 2006 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 4.00 | 4,000 | 16,000 | 16,000 | |
| Dec 12 2006 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Sell | S | 27.75 | 4,000 | 110,988 | 22,597 | 26.6 K to 22.6 K (-15.04 %) |
| Dec 12 2006 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 4.00 | 4,000 | 16,000 | 26,597 | 22.6 K to 26.6 K (+17.70 %) |
| Dec 06 2006 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 4.00 | 5,000 | 20,000 | 0 | |
| Dec 06 2006 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Sell | S | 28.00 | 5,000 | 140,000 | 26,690 | 31.7 K to 26.7 K (-15.78 %) |
| Dec 06 2006 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 4.00 | 5,000 | 20,000 | 31,690 | 26.7 K to 31.7 K (+18.73 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 4.00 | 5,000 | 20,000 | 5,000 | |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Sell | S | 26.91 | 5,000 | 134,565 | 26,690 | 31.7 K to 26.7 K (-15.78 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 4.00 | 5,000 | 20,000 | 31,690 | 26.7 K to 31.7 K (+18.73 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 5,000 | 26,650 | 243,000 | |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 7,000 | 37,310 | 248,000 | |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 26.91 | 5,000 | 134,565 | 640,987 | 646 K to 641 K (-0.77 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 5,000 | 26,650 | 645,987 | 641 K to 646 K (+0.78 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 26.75 | 7,000 | 187,278 | 640,987 | 648 K to 641 K (-1.08 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 7,000 | 37,310 | 647,987 | 641 K to 648 K (+1.09 %) |
| Nov 29 2006 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 4.00 | 4,000 | 16,000 | 20,000 | |
| Nov 29 2006 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Sell | S | 28.05 | 4,000 | 112,188 | 22,597 | 26.6 K to 22.6 K (-15.04 %) |
| Nov 29 2006 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 4.00 | 4,000 | 16,000 | 26,597 | 22.6 K to 26.6 K (+17.70 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | M | 4.00 | 5,000 | 20,000 | 48,000 | |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | M | 4.00 | 3,000 | 12,000 | 53,000 | |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | M | 4.00 | 2,000 | 8,000 | 56,000 | |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Sell | S | 27.15 | 5,000 | 135,735 | 24,181 | 29.2 K to 24.2 K (-17.13 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Buy | M | 4.00 | 5,000 | 20,000 | 29,181 | 24.2 K to 29.2 K (+20.68 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Sell | S | 27.15 | 3,000 | 81,450 | 24,181 | 27.2 K to 24.2 K (-11.04 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Buy | M | 4.00 | 3,000 | 12,000 | 27,181 | 24.2 K to 27.2 K (+12.41 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Sell | S | 27.15 | 2,000 | 54,302 | 24,181 | 26.2 K to 24.2 K (-7.64 %) |
| Dec 05 2006 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Buy | M | 4.00 | 2,000 | 8,000 | 26,181 | 24.2 K to 26.2 K (+8.27 %) |
| Nov 17 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 17.19 | 1,500 | 25,785 | 13,500 | |
| Nov 17 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 13.63 | 500 | 6,813 | 4,500 | |
| Nov 17 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 28.94 | 1,500 | 43,403 | 33,579 | 35.1 K to 33.6 K (-4.28 %) |
| Nov 17 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 17.19 | 1,500 | 25,785 | 35,079 | 33.6 K to 35.1 K (+4.47 %) |
| Nov 17 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 28.92 | 500 | 14,461 | 33,579 | 34.1 K to 33.6 K (-1.47 %) |
| Nov 17 2006 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 13.63 | 500 | 6,813 | 34,079 | 33.6 K to 34.1 K (+1.49 %) |
| Nov 17 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 5,000 | 26,650 | 255,000 | |
| Nov 17 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 7,000 | 37,310 | 260,000 | |
| Nov 17 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 29.26 | 5,000 | 146,290 | 640,987 | 646 K to 641 K (-0.77 %) |
| Nov 17 2006 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 5,000 | 26,650 | 645,987 | 641 K to 646 K (+0.78 %) |